Zacks Research Issues Optimistic Estimate for BMY Earnings

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at Zacks Research raised their Q1 2027 earnings per share estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Wednesday, May 7th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.41 for the quarter, up from their previous forecast of $1.34. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share.

BMY has been the topic of a number of other research reports. Citigroup raised their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Jefferies Financial Group decreased their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Finally, Piper Sandler began coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $1.60 during midday trading on Monday, hitting $45.72. 27,423,080 shares of the company were exchanged, compared to its average volume of 13,260,169. The firm's 50 day moving average price is $53.69 and its two-hundred day moving average price is $56.06. The firm has a market capitalization of $93.04 billion, a P/E ratio of -10.34, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period last year, the business posted ($4.40) earnings per share.

Hedge Funds Weigh In On Bristol-Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $1,989,525,000. Wellington Management Group LLP grew its holdings in shares of Bristol-Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock valued at $1,447,198,000 after purchasing an additional 17,750,938 shares during the last quarter. Ameriprise Financial Inc. raised its position in Bristol-Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. GQG Partners LLC grew its stake in shares of Bristol-Myers Squibb by 22,647.6% during the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock valued at $733,310,000 after buying an additional 11,970,598 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Bristol-Myers Squibb by 701.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after buying an additional 10,913,708 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.42%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is presently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.